The new results for Retatrutide are nothing short of impressive.
Beyond the substantial weight loss, we see improvements in several of the most important risk markers for cardiovascular disease: triglycerides down 40%, LDL cholesterol down 20%, hsCRP (inflammation) down 63%, and blood pressure down by a full 12 mmHg.
If these effects hold up over time, it is not hard to imagine that this type of treatment could have a significant impact on future cardiovascular disease and kidney disease.
We are moving from treating individual risk factors to influencing several of the most important drivers of ageing and chronic disease, all at once.
Exciting times in preventive medicine.
